Description

Tirzepatide, known also as LY3298176, represents a groundbreaking development in the pharmacological management of type 2 diabetes (T2D) and obesity. It’s a synthetic peptide that functions as a dual agonist for both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual mechanism is significant because it mimics the effects of endogenous GIP while simultaneously promoting cAMP synthesis at the GLP-1 receptor, leading to a synergistic effect. This results in enhanced insulin response and reduced glucagon levels, outperforming the impact of either GIP or GLP-1 therapies when used independently.

Tirzepatide is a 39 amino acid long peptide, which includes a C20 fatty di-acid moiety. This design grants it an extended duration of action, allowing for a once-weekly dosing regimen in humans. Its efficacy and safety in improving blood sugar control have led to its approval by the United States Food and Drug Administration (USFDA) in May 2022 for treating T2D. This marked it as the first dual GLP-1 and GIP receptor agonist for this purpose.

In addition to its application in diabetes, Tirzepatide is under investigation for its potential in weight management. Clinical trials have indicated significant and sustained benefits in weight loss, particularly in adults with a Body Mass Index (BMI) of 27 or higher. This is partly attributed to its ability to activate GIP receptors in fat cells, which seems to reduce adipose inflammation and enhance adiponectin production – factors known to reduce fat cell differentiation and increase energy expenditure.

The drug’s unique mechanism, encompassing mimicking native GIP at the GIP receptor and displaying a bias at the GLP-1 receptor for cAMP generation over beta-arrestin recruitment, is believed to underlie its effectiveness as an anti-diabetes drug. Tirzepatide has shown superior efficacy in glycemic control and comparable safety to other established T2D treatments in clinical trials. Additionally, its role in increasing serum adiponectin levels – an adipokine linked to lipid and glucose metabolism regulation – suggests potential cardioprotective implications.

Beyond its approved use as a T2D treatment, Tirzepatide is available for research to qualified professionals. Its multiple effects, including weight loss, improved glycemic control, and potential cardioprotective benefits, make it a subject of ongoing research and interest. The results of these studies, particularly those investigating its long-term effects and comprehensive cardiovascular outcomes, are eagerly anticipated by the medical community. Peptide products will be delivered as lyophilized powder and will need to be reconstituted. This should be considered when placing your order and before checkout.  Consider adding sufficient supply of Sterile Swabs, Syringes and BAC water before checkout.

Certificate of Analysis (COA)